® SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint ...

Core Insights - Inhibrx Biosciences, Inc. reported financial results for Q3 2025, highlighting the completion of the sale of INBRX-101 to Sanofi S.A. and the spin-off of Inhibrx as a standalone entity [1][4] - The company has two ongoing clinical programs, with positive topline results from the registrational trial of ozekibart (INBRX-109) in chondrosarcoma [2][9] - Inhibrx plans to submit a biologics license application to the U.S. FDA in Q2 2026 [6] Recent Corporate Highlights - On October 23, 2025, Inhibrx announced positive topline results from its trial of ozekibart in chondrosarcoma, demonstrating significant improvement in median progression-free survival compared to placebo [2][6] - Interim data from expansion cohorts in colorectal cancer and Ewing sarcoma show high response and disease control rates in heavily pretreated patients [6] Financial Results - As of September 30, 2025, Inhibrx had cash and cash equivalents of $153.1 million, down from $186.6 million as of June 30, 2025 [6] - Research and development expenses for Q3 2025 were $28.5 million, a decrease from $38.9 million in Q3 2024, primarily due to reduced process development and manufacturing activities [6][7] - General and administrative expenses were $5.3 million in Q3 2025, down from $7.9 million in Q3 2024, attributed to decreased legal and personnel-related expenses [6][7] - The net loss for Q3 2025 was $35.3 million, or $2.28 per share, compared to a net loss of $43.9 million, or $2.84 per share, in Q3 2024 [6][7] Summary of Financial Performance - Total revenue for Q3 2025 was $1.3 million, compared to $0.1 million in Q3 2024 [7] - Total operating expenses for Q3 2025 were $33.8 million, down from $46.8 million in Q3 2024 [7] - The company reported total liabilities of $140.6 million as of September 30, 2025, with stockholders' equity at $36.8 million [7]

Core Insights - Inhibrx Biosciences, Inc. is set to present clinical data on its DR5 Agonist at multiple upcoming scientific conferences, highlighting its focus on novel biologic therapeutic candidates [1][2][3] Conference Presentations - The company will present at the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium on November 5, 2025, discussing DR5 Agonist clinical data in various cancers [1] - At the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting from November 12-15, 2025, Inhibrx will present results from the Phase 2 ChonDRAgon Study on ozekibart (INBRX-109) in conventional chondrosarcoma [2] - The Society for NeuroOncology (SNO) 2025 Annual Meeting from November 19-23, 2025, will feature a poster presentation on the anti-tumor activity of ozekibart in GBM models [3] Company Overview - Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, utilizing diverse protein engineering methods [4] - The company was incorporated in January 2024 and has a current clinical pipeline that includes ozekibart and INBRX-106, both employing multivalent formats for optimized agonist function [4]

Core Insights - The biotech sector is experiencing significant momentum, with many clinical-stage and commercial biopharma stocks reaching new 52-week highs due to breakthrough trial data, strategic deals, and earnings surprises [1] Company Summaries - **Metsera Inc. (MTSR)**: A clinical-stage biopharmaceutical company focused on developing hormone analog peptides for obesity and related metabolic diseases. Recently, Novo Nordisk made a $9 billion unsolicited acquisition proposal, which Metsera's board considers superior to its existing agreement with Pfizer [2][3]. Metsera announced positive Phase 2b results for its GLP-1 receptor agonist MET-097i, showing up to 14.1% weight loss after 28 weeks, supporting Phase 3 initiation in late 2025 [4]. The stock rose from $32.35 to a 52-week high of $66.10, a gain of 104.3% [5]. - **Indivior Plc (INDV)**: Develops buprenorphine-based therapies for opioid dependence. The company reported Q3 net income of $42 million, up from $22 million a year ago, with adjusted earnings of $93 million, exceeding Wall Street's expectations [6][7]. The stock increased from $20.86 to a 52-week high of $30.55, reflecting a 46.5% gain [7]. - **Insmed Inc. (INSM)**: Focused on therapies for serious and rare diseases, Insmed reported a Q3 net loss of $370 million but saw net product revenue rise to $142.3 million from $93.4 million last year [8][9]. The company raised its full-year 2025 revenue guidance for ARIKAYCE to $420 million - $430 million, indicating 15% - 18% growth year-over-year [10]. The stock surged from $76.54 to a 52-week high of $194.70, marking a 154.4% gain [10]. - **Ventyx Biosciences Inc. (VTYX)**: A clinical-stage biotech company developing therapies for autoimmune and neurodegenerative diseases. Ventyx reported positive Phase 2 results for its NLRP3 inhibitor VTX3232, showing strong safety and tolerability [11][13]. The stock rose from $3.01 to a 52-week high of $8.52, a gain of over 183% [14]. - **Inhibrx Biosciences Inc. (INBX)**: Focuses on oncology and rare diseases, announcing positive topline results from its ChonDRAgon study for ozekibart in chondrosarcoma [15]. The stock increased from $18.35 to a 52-week high of $83.78, representing a gain of 356.6% [16]. - **ABIVAX Société Anonyme (ABVX)**: Developing therapies for chronic inflammatory diseases, ABIVAX presented positive Phase 3 data for obefazimod in ulcerative colitis [17]. The stock rose from $7.83 to an all-time high of $106.73, marking a significant gain of 1263% [18]. - **Arrowhead Pharmaceuticals Inc. (ARWR)**: Developing RNAi-based therapies, Arrowhead finalized a licensing agreement with Novartis for ARO-SNCA, with financial terms including a $200 million upfront payment [19][20][21]. The stock increased from $29.70 to a 52-week high of $43.33, representing a gain of over 45% [21]. - **Kodiak Sciences Inc. (KOD)**: Focused on retinal diseases, Kodiak announced positive Phase 1b data for KSI-101, showing significant vision improvements [22][23][24]. The stock climbed from $8.98 to a 52-week high of $21.17, delivering a 135.7% gain [22]. - **Arcutis Biotherapeutics Inc. (ARQT)**: Focused on dermatological treatments, Arcutis reported Q3 net income of $7.4 million, a turnaround from a net loss last year, with revenue up 122% year-over-year [25][26]. The stock rose from $14.99 to a 52-week high of $27.08, representing a gain of over 80% [27]. - **Maze Therapeutics Inc. (MAZE)**: Developing precision therapies for various diseases, Maze announced positive Phase 1 results for MZE782 and secured $150 million in a private placement [28][29]. The stock rose from $11.21 to a new 52-week high of $34.29, returning a gain of 206% [29]. - **Supernus Pharmaceuticals Inc. (SUPN)**: Focused on CNS disorders, Supernus is expected to report Q3 earnings of $0.82 per share and revenue of $180.22 million [30][31]. The stock increased from $38.21 to a 52-week high of $57.65, representing a gain of over 50% [31].

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s (INBX.US) DR5-targeting antibody, ozekibart, in treating advanced or metastatic, unresectable sarcoma patients [1] Company Summary - Chuangsheng Group's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] - The company holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1] Industry Summary - Inhibrx Biosciences announced positive primary results from a registrational clinical study evaluating the efficacy of ozekibart compared to placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Inhibrx plans to submit a marketing application for ozekibart for soft tissue sarcoma indications to U.S. regulatory authorities by the end of June 2026 [1]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s drug ozekibart, which is aimed at treating advanced or metastatic, unresectable soft tissue sarcoma [1] Group 1: Stock Performance - Chuangsheng Group-B's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] Group 2: Clinical Research Results - Inhibrx Biosciences, Inc. announced positive primary results from a registrational clinical study of ozekibart, a DR5 agonistic antibody, comparing its efficacy against a placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Based on these results, Inhibrx plans to submit a marketing application for the soft tissue sarcoma indication to U.S. regulatory authorities by the end of June 2026 [1] Group 3: Development Rights - Chuangsheng Group holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study, evaluating the efficacy of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Market Implications - Inhibrx plans to submit a New Drug Application (NDA) to the U.S. regulatory authorities for ozekibart's chondrosarcoma indication by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through its wholly-owned subsidiary, HJB [1] Group 3: Market Context - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market value of ozekibart for global patients and in the regions where the company has exclusive rights [1]

Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study evaluating ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma patients, leading to plans for a U.S. regulatory submission by June 2026 [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart compared to placebo [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Commercial Plans - Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] Group 3: Market Implications - The encouraging clinical data reinforces the value of ozekibart for global patients and in regions where the company has exclusive rights [1] - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market opportunity for ozekibart [1]

Core Insights - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical trial (n=206) evaluating ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] - Based on these results, Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - Ozekibart is the first investigational drug to significantly improve progression-free survival (PFS) in chondrosarcoma patients in a randomized controlled trial, addressing a significant unmet medical need [1] Company Developments - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] - Inhibrx is also advancing an expanded cohort for ozekibart, assessing its combination with irinotecan for the treatment of Ewing sarcoma and colorectal cancer, with early results showing promising signals [2]

Group 1 - The core point of the news is that Inhibrx Biosciences, Inc. has reported positive primary results from the ChonDRAgon clinical study, which evaluated the efficacy of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to a placebo [1] - Based on the positive results, Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - Ozekibart is the first investigational drug to significantly improve progression-free survival (PFS) in chondrosarcoma patients in a randomized controlled trial, addressing a significant unmet medical need as there are currently no approved systemic treatment options for this disease [1] Group 2 - In addition to the registration clinical trial, Inhibrx is advancing an expanded cohort to evaluate ozekibart in combination with irinotecan for the treatment of Ewing sarcoma and colorectal cancer [2] - Early results from this expanded cohort show encouraging signals, supporting further exploration of ozekibart's potential in these difficult-to-treat tumors with unmet medical needs [2]